[1] Harshad D, Guruprasad A, Sombat T, et al. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines[J]. Hepatol Int,2021,15(2):258-282. [2] Fernando B, Einar S B. Drug-Induced Liver Injury due to Biologics and Immune Check Point Inhibitors[J]. Med Clin North Am,2023,107(3):623-640. [3] 李变利, 徐丽红. 药物性肝损伤, 药物诱导性自身免疫性肝炎和自身免疫性肝炎鉴别诊断研究进展[J]. 实用肝脏病杂志,2021,24(4):460-463. [4] Zhen ZZ, Wu P, Juan Z, et al. Association of LEPR polymorphisms with predisposition and inflammatory response in anti-tuberculosis drug-induced liver injury: A pilot prospective investigation in Western Chinese Han population[J]. Infect Genet Evol,2019,75(10):103970-103970. [5] Akemi T, Kenichi H, Koichi T, et al. Histopathological analysis of autoimmune hepatitis with "acute" presentation: Differentiation from drug-induced liver injury[J]. Hepatol Res,2020,50(9):1047-1061. [6] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 中华肝脏病杂志,2015,23(11):810-820. [7] Jing JH, Kang ZZ, Xia CH, et al. Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor[J]. Front Pharmacol,2022,13(1):804189-804189. [8] 徐世风, 王旭昇, 曹磊. 122例药物性肝损伤患者的临床分型、严重程度及预后相关的MRI特征分析[J]. 肝脏,2023,28(9):1093-1096. [9] Edmond A, Cristiana F, Ismael A A, et al. Biomarkers of idiosyncratic drug-induced liver injury (DILI)-a systematic review[J]. Expert Opin Drug Meta Toxico,2021,17(11):1327-1343. [10] Hui QL, Feng C, Fei W. The immunological mechanisms and therapeutic potential in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity[J]. Cell Biosci,2022,12(1):187-187. [11] Yu Z, Hui G, Yu Z, et al. Correlation between serum cytokines and clinicopathological features in patients with drug-induced liver injury[J]. Front Pharmacol,2022,13(8):1070802-1070802. [12] 赖雪莹, 刘斌, 胡学琴, 等. 异甘草酸镁对紫杉醇致大鼠肝损伤的防治作用及其对血清IL-6、IL-10、TNF-α的影响[J]. 中华临床医师杂志(电子版),2020,14(11):922-925. [13] Yang ZX, Ermei C, Xi XYO, et al. Metabolomics and Cytokine Analysis for Identification of Severe Drug-Induced Liver Injury[J]. J Proteome Res,2019,18(6):2514-2524. [14] 李标, 孔化文, 李玉红, 等. IL-10启动子区基因多态性与抗结核药物性肝损伤关系[J]. 中华疾病控制杂志,2019,23(1):56-59,74. [15] Rong HX, Yun L, Xuan C, et al. Serum levels of IL-6/IL-10/GLDH may be early recognition markers of anti-tuberculosis drugs (ATB) -induced liver injury[J]. Toxicol Appl Pharmacol,2023,475(23):116635-116635. [16] 李应, 陈挥, 谢青, 等. 药物性肝损伤的生物标志物研究进展[J].肝脏,2022,27(12):1258-1263. [17] Gerussi A, Natalini A, Antonangeli F, et al. Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models[J]. Int J Mol Sci,2021,22(9):4557-4557. [18] 杨开宁, 王梦梦, 陈秀秀, 等. 不同护肝药物护佑抗痨治疗防治药物性肝损伤发生研究[J]. 实用肝脏病杂志,2023,26(3):384-387. [19] 刘海涛, 张雷鸣, 李经纬. 药物性肝损伤患者临床与病理学特征分析[J]. 实用肝脏病杂志,2022,25(4):508-511. |